DeltEx Allo - Model INB-100 - Allogeneic Product
INB-100, our DeltEx Allo, is an allogeneic product candidate, initially developed for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation (HSCT). This is the first clinical trial of an expanded and activated allogeneic gamma delta T cell immunotherapy.
HSCT procedures have increased over the last 20 years, with over 9,000 patients treated in the United States in 2018. Our scientific founder, Dr. Lawrence Lamb, Ph.D., was the first to describe a survival benefit in HSCT patients with naturally elevated levels of gamma-delta T cells. INB-100 was designed to translate this observation into a treatment and provides donor derived allogeneic gamma-delta T cells to patients following their HSCT. We are conducting a Phase 1 dose escalation clinical trial of INB-100 at the University of Kansas Cancer Center.